Efficacy of Nine-valent Pneumococcal Conjugate Vaccine Against Pneumonia and Invasive Pneumococcal Disease in The Gambia: Randomized Double-Blind, Placebo-Controlled Trial
Published in The Lancet, this study aims to assess the efficacy of a nine-valent pneumococcal conjugate vaccine in children through a randomised, placebo-controlled, double-blind trial in eastern Gambia. Children age 6–51 weeks were randomly allocated three doses of either pneumococcal conjugate vaccine (n=8718) or placebo (8719), with intervals of at least 25 days between doses. Our primary outcome was first episode of radiological pneumonia. Secondary endpoints were clinical or severe clinical pneumonia, invasive pneumococcal disease, and all-cause admissions. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author(s): Cutts U, Zaman SMA, Enwere G, et al.
Visit web page (English)
(Located at www.sciencedirect.com)
Citation: Cutts U, Zaman SMA, Enwere G, et al. Efficacy of Nine-valent Pneumococcal Conjugate Vaccine Against Pneumonia and Invasive Pneumococcal Disease in The Gambia: Randomized Double-blind, Placebo-controlled Trial. The Lancet. 2005;365(9465):1139-1146.